74,311 individuals had been enrolled in trials classified as active and not recruiting at time of funding termination.

HealthDay News — Women with persistent thyroid hormone imbalance across pregnancy may have an increased risk of having children with autism spectrum disorder (ASD), according to a study published ...

HealthDay News — Early use of higher-efficacy therapies is recommended for patients with moderately to severely active Crohn disease (CD), according to a living clinical practice guideline issued by ...

Tinlarebant is a novel oral therapy designed to reduce the build-up of bisretinoids, vitamin A-based toxins that lead to retinal complications in STGD1.

HealthDay News — Routine first-trimester ultrasounds lead to earlier detection of fetal anomalies, according to a study published online November 25 in PLOS Medicine.

The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to olezarsen as an adjunct to diet to reduce triglyceride (TG) levels in adults with severe hypertriglyceridemia (TG ...

HealthDay News — Obstructive sleep apnea (OSA) seems to be an independent risk factor for development of Parkinson disease, and early use of continuous positive airway pressure (CPAP) could modify the ...

If approved, the new autoinjector formulation would allow patients to administer furosemide at home reducing administration time from 5 hours to under 10 seconds.

HealthDay News — Trajectories of long COVID have been identified, according to a study published online November 17 in Nature Communications.

The Food and Drug Administration (FDA) has granted accelerated approval to Voyxact ® (sibeprenlimab-szsi) to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for ...

Extensive safety testing and manufacturing improvements have now made it possible to bring the drug back to the US market.

The FDA’s Priority Review designation allows for a shortened review period (within 6 months) from the time of application acceptance.